Navigation Links
KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone

NORTH LIBERTY, Iowa and LAS VEGAS, Sept. 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced the advancement of a new pain therapy program, KP606, a first-in-class oral prodrug of oxycodone.  KP606 adds to the Company's franchise of abuse-deterrent prodrugs, which includes KP201 (hydrocodone) and KP511 (hydromorphone).

KemPharm announced the discovery of KP606 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.  

In preclinical studies, KP606 exhibited superior pharmacological characteristics that suggest an improved safety profile compared to currently marketed oxycodone products, possibly reducing or preventing symptoms of constipation and limiting abuse potential. KP606 also features tamper resistant properties that make it difficult to extract oxycodone from the prodrug, which is not active until cleaved in the body.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "With the discovery of KP606, KemPharm now has the most complete – and advanced – pipeline of abuse-deterrent opioid prodrugs in development. Oxycodone, along with hydrocodone and hydromorphone, are not only the most prescribed opioid-based pain medications, but are three of the most prescribed drugs in the entire world.  As we continue towards an NDA filing for KP201 in the second quarter of 2014, KemPharm's goal is to re-define the pain management market by developing a franchise of therapeutics that offer unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation."

About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.comFor KemPharm, Inc:

Media / Investor Contacts:Christal Mickle

Jason Rando / Joshua Drumm, Ph.D. 319-665-2575 

Tiberend Strategic Advisors,

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharms KP201 to be Featured at PAINWeek 2013
2. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
3. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
4. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
5. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
6. Device Sector Facing Medical Education Challenges as Industry Continues Expansion into Emerging Markets
7. Americas Obsession with New "Anti-Aging" Pill Continues
8. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
9. The Kenneth Rainin Foundation Continues its Commitment to Ending Inflammatory Bowel Disease, Awarding $1.5 Million in Research Grants
10. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
11. American Pacific Board Continues Focus On Corporate Governance With Appointment Of Independent Lead Director
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO Medical ... technology at the Radiological Society of ... Chicago November 29 – December ... designed to offer customers unrivaled versatility, enhanced user ... --> ...
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... 2015 Research and Markets ( ) ... Devices Market 2015-2019" report to their offering. ... this report, the author the present scenario and growth ... To calculate the market size, the report considers revenue ... Hormonal IUDs and copper IUDs. The report forecasts the ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion ... tool designed specially for Final Cut Pro X. FCPX users can ... easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and simple, ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
Breaking Medicine News(10 mins):